Ganetespib is under clinical development by Aldeyra Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ganetespib’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 28 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 28 Jun 2022 increased Ganetespib’s Phase Transition Success Rate (PTSR) for Fallopian Tube Cancer, and increased PTSR for Peritoneal Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ganetespib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ganetespib overview

Ganetespib (STA-9090) is under development for the treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant peripheral nerve sheath tumors, sarcomas, malignant pleural mesothelioma. The drug candidate is administered through intravenous route. It is a synthetic, small-molecule that acts by targeting heat shock protein 90 (Hsp90).

It was also under development for the treatment of coronavirus disease 2019 (COVID-19).

It was under development for the treatment of  ocular melanoma, melanoma, hematological cancers including acute lymphoblastic leukemia, chronic myelogenous leukemia, post-transplant  lymphoproliferative diseases, HER2 positive or triple negative breast cancer, squamous cell carcinoma of the head and neck (SCCHN) including oral cavity, oropharynx, larynx or hypopharynx, metastatic esophagogastric cancers, non-small cell lung cancer, relapsed and refractory small-cell lung cancer, metastatic colorectal cancer, rectal adenocarcinoma, gastrointestinal stromal tumor, hepatocellular carcinoma, metastatic pancreatic cancer, gastrointestinal carcinomas, non-squamous non-small cell lung carcinoma, urothelial carcinomas, relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.

Aldeyra Therapeutics overview

Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.

Quick View Ganetespib LOA Data

Report Segments
  • Innovator
Drug Name
  • Ganetespib
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.